[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,403
  • Shares Outstanding, K 19,086
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,570 K
  • EBIT $ -38 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 389.40% (+255.18%)
  • Historical Volatility 162.62%
  • IV Percentile 85%
  • IV Rank 63.49%
  • IV High 576.32% on 11/20/25
  • IV Low 64.29% on 08/15/25
  • Expected Move (DTE 8) 0.57 (18.08%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 101
  • Volume Avg (30-Day) 338
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 22,887
  • Open Int (30-Day) 23,511
  • Expected Range 2.58 to 3.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.53
  • Number of Estimates 2
  • High Estimate $-0.45
  • Low Estimate $-0.60
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) +19.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.72 +15.81%
on 07/31/26
3.36 -6.25%
on 07/17/26
-0.14 (-4.26%)
since 07/13/26
3-Month
2.66 +18.42%
on 06/16/26
16.00 -80.31%
on 06/10/26
-8.15 (-72.12%)
since 05/13/26
52-Week
2.66 +18.42%
on 06/16/26
16.00 -80.31%
on 06/10/26
-6.50 (-67.36%)
since 08/13/25

Most Recent Stories

More News
Elicio Therapeutics: Q2 Earnings Snapshot

Elicio Therapeutics: Q2 Earnings Snapshot

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in...

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition...

ELTX : 3.15 (+2.94%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised...

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”) , a clinical-stage biotechnology company developing next-generation immunotherapies...

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies...

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies...

ELTX : 3.15 (+2.94%)
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or “the Company”)...

ELTX : 3.15 (+2.94%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised...

ELTX : 3.15 (+2.94%)
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent...

ELTX : 3.15 (+2.94%)

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.26
1st Resistance Point 3.21
Last Price 3.15
1st Support Level 3.07
2nd Support Level 3.00
3rd Support Level 2.94

See More

52-Week High 16.00
Fibonacci 61.8% 10.90
Fibonacci 50% 9.33
Fibonacci 38.2% 7.76
Last Price 3.15
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.